Promontory Therapeutics

What Promontory Therapeutics does

Promontory Therapeutics is a privately held, clinical-stage biopharmaceutical company developing PT-112, a first-in-class small-molecule conjugate of pyrophosphate and platinum that induces immunogenic cell death (ICD) in cancer cells through inhibition of ribosomal biogenesis, ER stress, and mitochondrial dysfunction, leading to release of damage-associated molecular patterns and downstream activation of dendritic, NK, and T-cell immune responses. The company, founded in 2014 as Phosplatin Therapeutics and rebranded in May 2022, is headquartered in New York and operates with 11-50 employees across the US, Europe, and Asia. Its lead asset is being evaluated in Phase 2/3 trials across multiple oncology indications: metastatic castration-resistant prostate cancer (lead Phase 3-ready indication following a successful FDA End of Phase 2 meeting in May 2025), recurrent thymoma and thymic carcinoma (under a CRADA with the National Cancer Institute, leveraging FDA Orphan Drug designation), non-small cell lung cancer (in combination with Pfizer/Merck KGaA's avelumab), and relapsed/refractory multiple myeloma (also FDA Orphan Drug designated).

The company's proprietary features include PT-112's osteotropism - the pyrophosphate moiety confers bone-seeking properties that are mechanistically aligned with bone metastases in prostate cancer and multiple myeloma - and a distinct ICD mechanism that differentiates it from conventional platinum chemotherapies. PT-112 is protected by granted US patents covering immuno-modulatory applications (No. 11,439,619) and bone/blood cancer treatment (No. 10,668,080). PT-112's clinical signal includes a 30% objective response rate in recurrent thymoma (3 of 10 evaluable patients), 60% of RECIST-evaluable patients achieving stable disease or better in the avelumab combination, 4 of 14 mCRPC patients achieving >50% PSA reduction, and immune activation data presented at AACR 2025.

Promontory Therapeutics is pre-revenue with no commercialized products; revenue mechanics to date are limited to milestone and royalty payments from the Greater China sub-license with SciClone Pharmaceuticals (signed 2015). The go-to-market model for the US and Europe will be determined post-Phase 3 read-out, with the company likely to evaluate partnering or co-promotion options. To date the company has raised approximately $56 million in equity capital (notably a $37M Series A in December 2021), and its commercialization channels are not yet established.

Name

Promontory Therapeutics

Legal name

Promontory Therapeutics Inc.

Website

https://promontorytx.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Promontory Therapeutics is a clinical-stage biopharmaceutical company developing PT-112, a first-in-class small-molecule immunogenic cell death inducer, for multiple oncology indications including metastatic castration-resistant prostate cancer, thymic epithelial tumors, NSCLC, and multiple myeloma.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Oncology drug development
• Immunogenic cell death
• Small molecule immunotherapy
• Cancer therapeutics
• Clinical-stage biotechnology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Clinical-stage biotech company developing PT-112 through Phase 2/3 clinical trials for multiple oncology indications. Revenue will be generated through product sales upon regulatory approval. The company has sub-licensed PT-112 for Greater China and receives milestone fees from its sub-licensee.
2. Licensing and Milestone Payments: Sub-license agreement for Greater China development and commercialization generates upfront, milestone, and royalty payments based on commercial sales in the territory.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Promontory Therapeutics is a clinical-stage biopharmaceutical company developing PT-112, a proprietary small-molecule conjugate of pyrophosphate that induces immunogenic cell death in cancer cells. The company is currently advancing PT-112 through Phase 2 clinical trials targeting metastatic castration-resistant prostate cancer (mCRPC), thymic epithelial tumors, non-small cell lung cancer, and multiple myeloma, with plans to commence a registrational Phase 3 study in mCRPC following a successful End of Phase 2 meeting with the FDA. Future revenue will be derived from product sales upon approval and from sub-licensing royalties (e.g., Greater China sub-license to SciClone).

Product overview

Promontory Therapeutics is a clinical-stage pharmaceutical company advancing a single lead therapeutic candidate, PT-112, which is a novel small molecule immunotherapy drug for oncology. PT-112 is the first small-molecule conjugate of pyrophosphate in clinical development and works by inducing immunogenic cell death (ICD) through inhibition of ribosomal biogenesis and organelle stress, leading to release of damage-associated molecular patterns (DAMPs) that activate dendritic cells and downstream immune effector cell recruitment. The drug candidate is being evaluated in multiple Phase 2 clinical trials for metastatic castration-resistant prostate cancer, thymic epithelial tumors, and non-small cell lung cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• PT-112 PT-112 is a novel small-molecule conjugate of pyrophosphate and platinum that induces immunogenic cell death (ICD) in cancer cells via ribosomal biogenesis inhibition, endoplasmic reticulum stress, mitochondrial dysfunction, and release of damage-associated molecular patterns (DAMPs). It is the first small-molecule conjugate of pyrophosphate in clinical development in oncology. The compound also exhibits osteotropism, concentrating in bone to address bone metastases. Indicated for clinical investigation in metastatic castration-resistant prostate cancer (mCRPC), thymic epithelial tumors, non-small cell lung cancer, and relapsed/refractory multiple myeloma.

Quantifiable outcome

• 30% objective response rate (3 partial responses among 10 evaluable patients) in recurrent thymoma Phase 2 trial
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Paris-Saclay Cancer ClusterminorStrategic or Co-development Partner · 29 September 2023Selected as the first international company member of Europe's emerging biotech hub for oncology. Part of company's expansion into France where clinical trials are conducted. Cluster is located near Paris, France.
• Baxter BioPharma SolutionsminorImplementation/ SI/ Consulting Partner · 7 November 2019Manufacturing partnership for cGMP drug product production of PT-112 at Halle/Westfalen, Germany facility. First fully-robotic cGMP batch completed, representing scale-up measure and advancement of CMC capabilities for pre-commercial manufacturing.
• Pfizer and Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development Partner · 9 September 2017Collaboration agreement to evaluate PT-112 in combination with avelumab (PD-L1 checkpoint inhibitor) in Phase Ib/II clinical trials. Promontory sponsors the trials; Pfizer and Merck KGaA supply avelumab. Combination showed safety and clinical benefit in heavily pre-treated solid tumor patients.
• SciClone Pharmaceuticals (Greater China sub-licensee)minorOEM/ Whitelabel/ Licensing Partner · 18 August 2015Regional licensing agreement for development and commercialization of PT-112 in Greater China (China, Hong Kong SAR, Macau SAR, Vietnam) with options for Taiwan and South Korea. SciClone receives milestone fees and royalties on commercial sales. Phase 1 trial conducted in Taiwan.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerFormal Collaborative Research and Development Agreement (CRADA) with NCI for Phase 2 study of PT-112 in thymic epithelial tumors. NCI Principal Investigator Arun Rajan, MD leads the single-site study (NCT05104736). PT-112 has received FDA Orphan Drug designation for this indication. NCI presented immune activation data at AACR 2025.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) designed to induce anti-tumor immune responses. Comparable to Promontory through its mechanistic focus on immune activation in tumors and clinical-stage development profile.
• Cardiff Oncology: Clinical-stage oncology company developing onvansertib, a small molecule, in metastatic castration-resistant prostate cancer (mCRPC). Highly comparable to Promontory's PT-112 by indication (mCRPC late-line), development stage (Phase 2/3), and small-molecule therapeutic modality.
• Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapeutics, including RP-3467 in mCRPC and other indications. Comparable to Promontory by clinical-stage profile, focus on oncology, and specific overlap in mCRPC development.
• Cogent Biosciences: Clinical-stage precision oncology company developing targeted small molecules (e.g., bezuclastinib) for genomically defined cancers. Comparable to Promontory as a clinical-stage small-molecule oncology company with a single lead asset advancing through registrational trials.
• Tempest Therapeutics: Clinical-stage immuno-oncology company advancing novel small molecules that engage the immune system to treat cancer. Comparable to Promontory in therapeutic modality (small-molecule IO), development stage (Phase 2/3), and strategy of pursuing indications with high unmet need.
• Arcus Biosciences: Clinical-stage immuno-oncology company with multiple programs targeting the adenosine pathway and other immune checkpoints. Comparable as a clinical-stage IO company pursuing combination strategies and indications with limited treatment options, similar in scale and development philosophy to Promontory.

Emerging players

• Compugen: Clinical-stage immuno-oncology company using computational discovery to identify novel drug targets in the tumor microenvironment. Comparable as a clinical-stage IO company pursuing novel immune mechanisms in cancer, though with a distinct computational platform approach.
• Werewolf Therapeutics: Clinical-stage oncology company developing PREDATOR platform with conditionally activated immune-engaging therapies. Comparable to Promontory as a clinical-stage IO company focused on novel immune-activating mechanisms in oncology, though with a distinct biologic (rather than small-molecule) platform.
• Surface Oncology: Clinical-stage immuno-oncology company developing antibodies targeting the tumor microenvironment. Comparable as a clinical-stage IO biotech pursuing immune-mediated anti-tumor activity, though focused on biologics rather than small molecules like PT-112.
• Bicycle Therapeutics: Clinical-stage oncology company developing bicyclic peptide therapeutics (Bicycles) for cancer. Comparable as a clinical-stage oncology company advancing novel therapeutic modalities through registrational trials, with overlapping investor audiences and development stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Phosplatin
• LinkedInlinkedin.com/company/phosplatin-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Promontory Therapeutics